Quote this publication Share Print

EYLEA

-
Opinions on drugs - Posted on Nov 05 2014

Reason for request

Extension of indication

-


Clinical Benefit

Substantial

Substantial


Clinical Added Value

no clinical added value
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).

Contact Us

Évaluation des médicaments
All our publications